SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
We’re going down soon, to move to a new Data Center today. We’ll be up ASAP. Sorry. |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/28/24 CASI Pharmaceuticals, Inc. 20-F 12/31/23 142:21M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size 1: 20-F Annual or Annual-Transition Report by a Foreign HTML 3.52M Non-Canadian Issuer 2: EX-1.1 Underwriting Agreement or Conflict Minerals Report HTML 1.36M 3: EX-2.1 Plan of Acquisition, Reorganization, Arrangement, HTML 58K Liquidation or Succession 4: EX-4.29 Instrument Defining the Rights of Security Holders HTML 230K 5: EX-4.37 Instrument Defining the Rights of Security Holders HTML 1.10M 6: EX-4.38 Instrument Defining the Rights of Security Holders HTML 321K 7: EX-4.39 Instrument Defining the Rights of Security Holders HTML 56K 8: EX-4.40 Instrument Defining the Rights of Security Holders HTML 336K 9: EX-4.41 Instrument Defining the Rights of Security Holders HTML 315K 10: EX-4.42 Instrument Defining the Rights of Security Holders HTML 140K 11: EX-4.43 Instrument Defining the Rights of Security Holders HTML 128K 12: EX-4.44 Instrument Defining the Rights of Security Holders HTML 121K 13: EX-4.45 Instrument Defining the Rights of Security Holders HTML 314K 14: EX-4.46 Instrument Defining the Rights of Security Holders HTML 92K 15: EX-4.47 Instrument Defining the Rights of Security Holders HTML 122K 16: EX-4.48 Instrument Defining the Rights of Security Holders HTML 60K 17: EX-8.1 Opinion of Counsel re: Tax Matters HTML 38K 21: EX-13.1 Annual or Quarterly Report to Security Holders HTML 41K 22: EX-13.2 Annual or Quarterly Report to Security Holders HTML 41K 24: EX-97.1 Clawback Policy re: Recovery of Erroneously HTML 62K Awarded Compensation 18: EX-11.1 Statement re: the Computation of Earnings Per HTML 67K Share 19: EX-12.1 Statement re: the Computation of Ratios HTML 44K 20: EX-12.2 Statement re: the Computation of Ratios HTML 44K 23: EX-15.1 Letter re: Unaudited Interim Financial Info HTML 38K 30: R1 Document and Entity Information HTML 115K 31: R2 Consolidated Balance Sheets HTML 147K 32: R3 Consolidated Balance Sheets (Parenthetical) HTML 50K 33: R4 Consolidated Statements of Operations and HTML 185K Comprehensive Loss 34: R5 Consolidated Statements of Stockholders' Equity HTML 90K 35: R6 Consolidated Statements of Cash Flows HTML 188K 36: R7 Description of Business HTML 87K 37: R8 Summary of Significant Accounting Policies HTML 96K 38: R9 Investment in Equity Securities, at Fair Value and HTML 187K Long-Term Investments 39: R10 Inventories HTML 41K 40: R11 Leases HTML 89K 41: R12 Property, Plant and Equipment HTML 61K 42: R13 Intangible Assets HTML 111K 43: R14 Accrued and Other Current Liabilities, and Other HTML 76K Liabilities 44: R15 Short Term Borrowings HTML 43K 45: R16 Notes Payable HTML 45K 46: R17 Grants HTML 42K 47: R18 Redeemable Noncontrolling Interest and Long Term HTML 68K Borrowing 48: R19 Shareholders' Equity HTML 66K 49: R20 Costs of Revenues HTML 40K 50: R21 Net Loss Per Share HTML 65K 51: R22 Employee Benefit Plan HTML 42K 52: R23 Share-Based Compensation HTML 182K 53: R24 Income Taxes HTML 159K 54: R25 Fair Value Measurements HTML 118K 55: R26 Related Party Transactions HTML 48K 56: R27 Commitments and Contingencies HTML 44K 57: R28 Restricted Net Assets HTML 41K 58: R29 Subsequent Events HTML 41K 59: R30 Condensed Financial Information of Registrant HTML 220K 60: R31 Summary of Significant Accounting Policies HTML 164K (Policies) 61: R32 Summary of Significant Accounting Policies HTML 50K (Tables) 62: R33 Investment in Equity Securities, at Fair Value and HTML 170K Long-Term Investments (Tables) 63: R34 Leases (Tables) HTML 88K 64: R35 Property, Plant and Equipment (Tables) HTML 57K 65: R36 Intangible Assets (Tables) HTML 111K 66: R37 Accrued and Other Current Liabilities, and Other HTML 76K Liabilities (Tables) 67: R38 Redeemable Noncontrolling Interest (Tables) HTML 61K 68: R39 Shareholders' Equity (Tables) HTML 53K 69: R40 Net Loss Per Share (Tables) HTML 64K 70: R41 Share-Based Compensation (Tables) HTML 180K 71: R42 Income Taxes (Tables) HTML 159K 72: R43 Fair Value Measurements (Tables) HTML 117K 73: R44 Condensed Financial Information of Registrant HTML 222K (Tables) 74: R45 DESCRIPTION OF BUSINESS - Liquidity and Capital HTML 111K Resources (Details) 75: R46 DESCRIPTION OF BUSINESS - License and Distribution HTML 51K Agreements (China Resources Pharmaceutical Commercial Group International Trading Co., Ltd.) (Details) 76: R47 DESCRIPTION OF BUSINESS - License and Distribution HTML 50K Agreements (Precision Autoimmune Therapeutics Co., Ltd) (Details) 77: R48 DESCRIPTION OF BUSINESS - License and Distribution HTML 47K Agreements (Juventas Cell Therapy Ltd.) (Details) 78: R49 DESCRIPTION OF BUSINESS - License and Distribution HTML 72K Agreements (BioInvent International AB) (Details) 79: R50 DESCRIPTION OF BUSINESS - License and Distribution HTML 54K Agreements (Black Belt Therapeutics Limited) (Details) 80: R51 DESCRIPTION OF BUSINESS - License and Distribution HTML 56K Agreements (Cleave Therapeutics, Inc.) (Details) 81: R52 DESCRIPTION OF BUSINESS - License and Distribution HTML 48K Agreements (Pharmathen Global BV) (Details) 82: R53 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 41K Consolidation (Details) 83: R54 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 40K Segment Reporting (Details) 84: R55 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash HTML 47K and Cash Equivalents (Details) 85: R56 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 46K Aggregate Cost And Fair Value (Details) 86: R57 Summary of Significant Accounting Policies - Ppe HTML 48K (Details) 87: R58 INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND HTML 66K LONG-TERM INVESTMENTS - Investment in equity securities, at fair value-MaxCyte Inc. (Details) 88: R59 INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND HTML 94K LONG-TERM INVESTMENTS - Investment in equity securities, at fair value-BioInvent International AB ordinary shares and warrants (Details) 89: R60 INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND HTML 71K LONG-TERM INVESTMENTS - BioInvent International AB - Summary of Investments (Details) 90: R61 INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND HTML 66K LONG-TERM INVESTMENTS - Summary of Long-term investments (Details) 91: R62 INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND HTML 86K LONG-TERM INVESTMENTS - Investment in equity securities, at fair value-Juventas Cell Therapy Ltd. (Details) 92: R63 INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND HTML 89K LONG-TERM INVESTMENTS - Investment in equity securities, at fair value-Alesta Therapeutics B.V. (Details) 93: R64 INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND HTML 78K LONG-TERM INVESTMENTS - Investment in equity securities, at fair value-Cleave Therapeutics, Inc. (Details) 94: R65 INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND HTML 75K LONG-TERM INVESTMENTS - Investment in Precision Autoimmune Therapeutics Co Ltd (Pat) (Details) 95: R66 Inventories (Details) HTML 43K 96: R67 Leases - (Details) HTML 57K 97: R68 Leases - Right of Use Assets and Liabilities HTML 51K (Details) 98: R69 LEASES - Supplemental Cash Flow (Details) HTML 45K 99: R70 LEASES - Future Undiscounted Cash Flows (Details) HTML 61K 100: R71 PROPERTY, PLANT AND EQUIPMENT - Narratives HTML 50K (Details) 101: R72 PROPERTY, PLANT AND EQUIPMENT - By type (Details) HTML 55K 102: R73 INTANGIBLE ASSETS - Narratives (Details) HTML 72K 103: R74 INTANGIBLE ASSETS - Net Definite-lived Intangible HTML 59K Assets (Details) 104: R75 INTANGIBLE ASSETS - Intangible Assets Rollforward HTML 50K (Details) 105: R76 INTANGIBLE ASSETS - Expected Future Amortization HTML 52K Expense (Details) 106: R77 Accrued and Other Current Liabilities, and Other HTML 73K Liabilities (Details) 107: R78 Short Term Borrowings (Details) HTML 63K 108: R79 Notes Payable (Details) HTML 50K 109: R80 Grants (Details) HTML 51K 110: R81 Redeemable Noncontrolling Interest and Long Term HTML 96K Borrowing (Details) 111: R82 Redeemable Noncontrolling Interest and Long Term HTML 51K Borrowing - Changes in Redeemable Noncontrolling Interest (Details) 112: R83 Shareholders' Equity (Details) HTML 83K 113: R84 Shareholders' Equity - Warrants Activity (Details) HTML 52K 114: R85 Costs of Revenues (Details) HTML 42K 115: R86 Net Loss Per Share (Details) HTML 43K 116: R87 Net Loss Per Share - Basic and diluted net loss HTML 70K per share computation (Details) 117: R88 Employee Benefit Plan (Details) HTML 44K 118: R89 SHARE-BASED COMPENSATION - Compensation Expense HTML 55K (Details) 119: R90 SHARE-BASED COMPENSATION - Weighted-Average HTML 55K Assumptions (Details) 120: R91 SHARE-BASED COMPENSATION - Options Outstanding HTML 95K (Details) 121: R92 SHARE-BASED COMPENSATION - Stock Option HTML 70K Outstanding (Details) 122: R93 Share-Based Compensation (Details) HTML 86K 123: R94 INCOME TAXES - Loss Before Income Taxes (Details) HTML 50K 124: R95 INCOME TAXES - Deferred Income Tax Assets And HTML 72K Liabilities (Details) 125: R96 INCOME TAXES - Reconciliation Of The Provision For HTML 65K Income Taxes (Details) 126: R97 INCOME TAXES - Valuation allowance (Details) HTML 47K 127: R98 INCOME TAXES - Gross Unrecognized Tax Benefits HTML 45K (Details) 128: R99 Income Taxes (Details) HTML 77K 129: R100 FAIR VALUE MEASUREMENTS - Financial and HTML 67K Non-Financial Assets and Liabilities (Details) 130: R101 FAIR VALUE MEASUREMENTS - Quantitative Information HTML 50K about Level 3 Fair Value Measurements (Details) 131: R102 Fair Value Measurements (Details) HTML 62K 132: R103 Related Party Transactions (Details) HTML 83K 133: R104 Commitments and Contingencies (Details) HTML 58K 134: R105 Restricted Net Assets (Details) HTML 40K 135: R106 CONDENSED FINANCIAL INFORMATION OF REGISTRANT - HTML 150K Condensed Balance Sheets (Details) 136: R107 CONDENSED FINANCIAL INFORMATION OF REGISTRANT - HTML 108K Condensed Statements of Operations and Comprehensive Loss (Details) 137: R108 CONDENSED FINANCIAL INFORMATION OF REGISTRANT - HTML 108K Condensed Statements of Cash Flows (Details) 139: XML IDEA XML File -- Filing Summary XML 243K 142: XML XBRL Instance -- casi-20231231x20f_htm XML 3.57M 138: EXCEL IDEA Workbook of Financial Report Info XLSX 249K 26: EX-101.CAL XBRL Calculations -- casi-20231231_cal XML 267K 27: EX-101.DEF XBRL Definitions -- casi-20231231_def XML 1.32M 28: EX-101.LAB XBRL Labels -- casi-20231231_lab XML 1.83M 29: EX-101.PRE XBRL Presentations -- casi-20231231_pre XML 1.74M 25: EX-101.SCH XBRL Schema -- casi-20231231 XSD 324K 140: JSON XBRL Instance as JSON Data -- MetaLinks 668± 1.06M 141: ZIP XBRL Zipped Folder -- 0001558370-24-004190-xbrl Zip 1.32M
|
This ‘20-F’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 3/28/24 | None on these Dates | ||
For Period end: | 12/31/23 | |||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/03/24 CASI Pharmaceuticals, Inc. F-3 4:521K |